Skip to main content Accessibility help
×
Home

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

  • Bruna Panizzutti (a1), Chiara Bortolasci (a2) (a3), Kyoko Hasebe (a3), Srisaiyini Kidnapillai (a3), Laura Gray (a3) (a4), Ken Walder (a3), Michael Berk (a5) (a6) (a4) (a7), Mohammadreza Mohebbi (a8), Seetal Dodd (a5) (a6) (a7), Clarissa Gama (a1), Pedro V. Magalhães (a1), Susan M. Cotton (a7) (a9), Flávio Kapczinski (a1), Ashley I. Bush (a6) (a4), Gin S. Malhi (a10) (a11) (a12) and Olivia M. Dean (a5) (a6) (a4)...

Abstract

Objective

This study aimed to explore effects of adjunctive treatment with N-acetyl cysteine (NAC) on markers of inflammation and neurogenesis in bipolar depression.

Methods

This is a secondary analysis of a placebo-controlled randomised trial. Serum samples were collected at baseline, week 8, and week 32 of the open-label and maintenance phases of the clinical trial to determine changes in interleukin (IL)-6, IL-8, IL-10, tumour necrosis factor-α (TNF-α), C-reactive protein (CRP) and brain-derived neurotrophic factor (BDNF) following adjunctive NAC treatment, and to explore mediation and moderator effects of the listed markers.

Results

Levels of brain-derived neurotrophic factor (BDNF), tumour necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukins (IL) -6, 8, or 10 were not significantly changed during the course of the trial or specifically in the open-label and maintenance phases. There were no mediation or moderation effects of the biological factors on the clinical parameters.

Conclusion

The results suggest that these particular biological parameters may not be directly involved in the therapeutic mechanism of action of adjunctive NAC in bipolar depression.

Copyright

Corresponding author

Author for correspondence: Dr. Olivia Dean, IMPACT SRC, School of Medicine, Deakin University, Kitchener House, P.O. Box 281, Geelong, VIC 3220, Australia. Tel: +61 3 4215 3300; Fax: 61 3 4215 3491; E-mail: oliviad@barwonhealth.org.au.

References

Hide All
1. Vancampfort, D, Vansteelandt, K, Correll, CU, Mitchell, AJ, De Herdt, A Sienaert, P, Probst, M De Herdt, M (2013) Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 170, 265274.
2. Alonso, J, Petukhova, M, Vilagut, G, Chatterji, S, Heeringa, S, Üstün, TB, Alhamzawi, AO, Viana, MC, Angermeyer, M, Bromet, E, Bruffaerts, R, de Girolamo, G, Florescu, S, Gureje, O, Haro, JM, Hinkov, H, Hu, CY, Karam, EG, Kovess, V, Levinson, D, Medina-Mora, ME, Nakamura, Y, Ormel, J, Vilagut, G, Posada-Villa, J, Sagar, R, Scott, KM, Tsang, A, Williams, DR Kessler, RC (2011) Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry 16, 12341246.
3. Grande, I, Berk, M, Birmaher, B Vieta, E (2016) Bipolar disorder. Lancet Lond Engl 387, 15611572.
4. Rosenblat, JD, Kakar, R, Berk, M, Kessing, LV, Vinberg, M, Baune, BT, Mansur, RB, Brietzke, E, Goldstein, BI McIntyre, RS (2016) Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 18, 89101.
5. Sigitova, E, Fišar, Z, Hroudová, J, Cikánková, T Raboch, J (2017) Biological hypotheses and biomarkers of bipolar disorder: hypotheses of bipolar disorder. Psychiatry Clin Neurosci 71, 77103.
6. Magalhães, PV, Dean, OM, Bush, AI, Copolov, DL, Weisinger, D, Malhi, GS, Kohlmann, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M Berk, M (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr Sao Paulo Braz 1999 33, 374378.
7. Magalhães, PV, da, S, Dean, OM, Bush, AI, Copolov, DL, Malhi, GS, Kohlmann, K, Jeavons, S, Schapkaitz, I, Anderson-Hunt, M Berk, M (2013) A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry 47, 564568.
8. Minarini, A, Ferrari, S, Galletti, M, Giambalvo, N, Perrone, D, Rioli, G Galeazzi, GM (2017) N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects. Expert Opin Drug Metab Toxicol 13, 279292.
9. Berk, M, Malhi, GS, Gray, LJ Dean, OM (2013) The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 34, 167177.
10. Samuni, Y, Goldstein, S, Dean, OM Berk, M (2013) The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta 1830, 41174129.
11. Dean, O, Giorlando, F Berk, M (2011) N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci JPN 36, 7886.
12. Berk, M, Dean, O, Cotton, SM, Gama, CS, Kapczinski, F, Fernandes, BS, Kohlmann, K, Jeavons, S, Hewitt, K, Allwang, C, Allwang, C, Cobb, H, Bush, AI, Schapkaitz, I, Dodd, S Malhi, GS (2011) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135, 389394.
13. Berk, M, Dean, OM, Cotton, SM, Gama, CS, Kapczinski, F, Fernandes, B, Kohlmann, K, Jeavons, S, Hewitt, K, Moss, K, Allwang, C, Schapkaitz, I, Cobb, H, Bush, AI, Dodd, S Malhi, GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med. 10, 91.
14. Kraemer, HC, Wilson, GT, Fairburn, CG Agras, WS (2002) Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59, 877883.
15. NCSS (2017) PASS 15 power analysis and sample size software. NCSS, LLC: Kaysville, Utah, USA.
16. Nascimento, MM, Suliman, ME, Silva, M, Chinaglia, T, Marchioro, J, Hayashi, SY, Riella, MC, Lindholm, B Anderstam, B (2010) Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. Perit Dial Int J Int Soc Perit Dial 30, 336342.
17. Paintlia, MK, Paintlia, AS, Singh, AK Singh, I (2008) Attenuation of lipopolysaccharide-induced inflammatory response and phospholipids metabolism at the feto-maternal interface by N-acetyl cysteine. Pediatr Res 64, 334339.
18. Paterson, RL, Galley, HF Webster, NR (2003) The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med 31, 25742578.
19. Lasram, MM, Dhouib, IB, Annabi, A, El Fazaa, S Gharbi, N (2015) A review on the possible molecular mechanism of action of N-acetylcysteine against insulin resistance and type-2 diabetes development. Clin Biochem 48, 12001208.
20. Rabie, MA, Mohsen, M, Ibrahim, M El-Sawy Mahmoud, R (2014) Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord 162, 6772.
21. Holdiness, MR (1991) Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet 20, 123134.
22. Dean, O, Bush, AI, Berk, M, Copolov, DL van den Buuse, M (2009) Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. Behav Brain Res 198, 258262.
23. Berk, M, Dean, OM, Cotton, SM, Jeavons, S, Tanious, M, Kohlmann, K, Hewitt, K, Moss, K, Allwang, C, Schapkaitz, I, Robbins, J, Cobb, H, Ng, F, Dodd, S, Bush, AI Malhi, GS (2014) The Efficacy of Adjunctive em N/em-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 75, 628636.
24. Fernandes, BS, Dean, OM, Dodd, S, Malhi, GS Berk, M (2016) N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry 77, 457466.

Keywords

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

  • Bruna Panizzutti (a1), Chiara Bortolasci (a2) (a3), Kyoko Hasebe (a3), Srisaiyini Kidnapillai (a3), Laura Gray (a3) (a4), Ken Walder (a3), Michael Berk (a5) (a6) (a4) (a7), Mohammadreza Mohebbi (a8), Seetal Dodd (a5) (a6) (a7), Clarissa Gama (a1), Pedro V. Magalhães (a1), Susan M. Cotton (a7) (a9), Flávio Kapczinski (a1), Ashley I. Bush (a6) (a4), Gin S. Malhi (a10) (a11) (a12) and Olivia M. Dean (a5) (a6) (a4)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed